LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Kidney Disease Biomarker May Indicate Lung Problems

By LabMedica International staff writers
Posted on 09 Oct 2018
Image: An albumin immunoturbidimetric assay urine or serum plasma; standard microalbumin range is 0.4-500mg/L (Photo courtesy of Sentinel Diagnostics).
Image: An albumin immunoturbidimetric assay urine or serum plasma; standard microalbumin range is 0.4-500mg/L (Photo courtesy of Sentinel Diagnostics).
Chronic lower respiratory diseases (CLRD) are the fourth leading cause-of-death and a major source of health care costs. CLRD includes chronic obstructive pulmonary disease (COPD), chronic bronchitis, emphysema, and asthma, airflow limitation as a physiologic correlate, and acute exacerbations as the major clinical manifestation.

Albuminuria is a commonly used biomarker of endothelial damage in the kidneys and correlates with microvascular dysfunction throughout the body, including in the pulmonary circulation. Cross-sectional studies suggest albuminuria is increased in COPD patients, among whom it is adversely associated with lung function, gas exchange, and hypoxia.

A large team of scientists working with the Columbia University College of Physicians & Surgeons (New York, NY, USA) conducted their study by pooling information from 31,877 participants (average age: 60 years) from six cohort studies. Urine albumin was measured by nephelometry or immunoturbidometry, and urine creatinine assessed by the Jaffe method. These were used to calculate the spot urine albumin-to-creatinine ratio, called “albuminuria.” Pre-bronchodilator lung function was measured using water-seal, dry-rolling-seal, or flow sensing spirometers. Incident moderate-to-severe COPD was defined as FEV1/FVC<LLN and FEV1<80% at the final spirometry exam.

The team reported that they found for each standard deviation increase in albuminuria, there was a 15% increase in those who developed moderate-to-severe COPD; a 26% increase in COPD hospitalizations and deaths; and 3% greater decline in FEV1 (the amount of air that can be forcibly exhaled in one second) and an 11% greater decline in the ratio between FEV1 and FVC (the total amount of air that can be forcibly exhaled after taking the deepest breath possible). Both FEV1 and FEV1/FVC are important measures of lung function.

Elizabeth C. Oelsner, MD, MPH, an Assistant Professor of Medicine and lead author of the study, said, “Our study helps to explain why COPD patients often have a constellation of vascular problems, including heart and kidney disease. This makes it all the more important for clinicians to encourage avoidance of exposures like smoking and treatment of diseases like hypertension and diabetes that cause endothelial dysfunction.” The study was published on September 28, 2018, in the American Journal of Respiratory and Critical Care Medicine.

Related Links:
Columbia University College of Physicians & Surgeons

Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
8-Channel Pipette
SAPPHIRE 20–300 µL

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more